4503 アステラス薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	2,139,245	382,633	17.9%	-	-	291,535	13.6%	162.77	11.9%	832.4%	0.0%	474.5%
2025/03	4Q	1,912,323	41,039	2.1%	-	-	50,747	2.7%	28.35	19.2%	60.8%	0.0%	197.7%
2024/03	4Q	1,603,672	25,518	1.6%	-	-	17,045	1.1%	9.51	5.6%	-80.8%	0.0%	-82.7%
2023/03	4Q	1,518,619	133,029	8.8%	-	-	98,714	6.5%	54.24	17.2%	-14.6%	0.0%	-20.4%
2022/03	4Q	1,296,163	155,686	12.0%	-	-	124,086	9.6%	67.08	3.7%	14.4%	0.0%	2.9%
2021/03	4Q	1,249,528	136,051	10.9%	-	-	120,589	9.7%	64.93	-3.9%	-44.2%	0.0%	-38.3%
2020/03	4Q	1,300,843	243,991	18.8%	-	-	195,411	15.0%	104.15	-0.4%	0.0%	0.0%	-12.1%
2019/03	4Q	1,306,348	243,912	18.7%	-	-	222,265	17.0%	115.05	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	2,139,245	382,633	17.9%	-	-	291,535	13.6%	162.77	11.9%	832.4%	0.0%	474.5%
2025/03	4Q	1,912,323	41,039	2.1%	-	-	50,747	2.7%	28.35	19.2%	60.8%	0.0%	197.7%
2024/03	4Q	1,603,672	25,518	1.6%	-	-	17,045	1.1%	9.51	5.6%	-80.8%	0.0%	-82.7%
2023/03	4Q	1,518,619	133,029	8.8%	-	-	98,714	6.5%	54.24	17.2%	-14.6%	0.0%	-20.4%
2022/03	4Q	1,296,163	155,686	12.0%	-	-	124,086	9.6%	67.08	3.7%	14.4%	0.0%	2.9%
2021/03	4Q	1,249,528	136,051	10.9%	-	-	120,589	9.7%	64.93	-3.9%	-44.2%	0.0%	-38.3%
2020/03	4Q	1,300,843	243,991	18.8%	-	-	195,411	15.0%	104.15	-0.4%	0.0%	0.0%	-12.1%
2019/03	4Q	1,306,348	243,912	18.7%	-	-	222,265	17.0%	115.05	-	-	-	-